All News
Bimekizumab Development Delayed by FDA
UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).
Read Article
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Read Article
Cool NEJM Case of Spinal Gout in 82-yr-old woman with 3-wk hx of severe LBP, rigors, anorexia, incomplete urination. Hx of PsA, CKD, CHF treated w/ Humira, HCQ, diuretics. Imaging tophi in spine, responded to steroids and allopurinol. https://t.co/JgH2bPsDeu https://t.co/RAPNxohe55
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available on Methotrexate Monitoring. Download wherever you get your podcasts.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.
https://t.co/TQiUMdS4R0 https://t.co/vgejiV3hUl
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t
Links:
Dr. John Cush RheumNow ( View Tweet)
ASCORE: Seropositivity Favors Abatacept Drug Survival
The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive.
https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf
Links:
Dr. John Cush RheumNow ( View Tweet)
Can You Reduce Frequency of Methotrexate Monitoring?
https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC
Links:
Dr. John Cush RheumNow ( View Tweet)
Wiki Guidelines Approach to Pyogenic Osteomyelitis
https://t.co/PaYolXmPv3 https://t.co/AXrwhRjQs4
Links:
Dr. John Cush RheumNow ( View Tweet)
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery.
https://t.co/ZhAiuFu8iw https://t.co/OsR6p9m2S9
Links:
Dr. John Cush RheumNow ( View Tweet)
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/qdC8VXC1ko https://t.co/C67sB6IFVL
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/I88bvuU4cg https://t.co/4xNH0IZnGA
Links:
Dr. John Cush RheumNow ( View Tweet)
Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/FJjDxm7wfQ https://t.co/EiuSGaXgeh
Links:
Dr. John Cush RheumNow ( View Tweet)
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl
Links:
Dr. John Cush RheumNow ( View Tweet)
Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA.
https://t.co/LFfZAFgMWE https://t.co/n8X45pInYQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth
Links:
Dr. John Cush RheumNow ( View Tweet)
2019 Gabapentin Rx=69 million; 7th most common Rx in USA. MMWR: 62,652 overdose deaths, 52% had Pos. gabapentin test. OD deaths w/ GAB involved usually involved illicitly manufactured fentanyls. GAB+Opioids=BAD COMBO! https://t.co/qQbPmwzAgJ
Links:
Dr. John Cush RheumNow ( View Tweet)
EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4
Dr. John Cush RheumNow ( View Tweet)
Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA.
https://t.co/spcdweO0pE https://t.co/0stEBPy6hc
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! Join us on May 17th for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.
https://t.co/s7r09y5KNG https://t.co/0KYRPwGHsV
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab's Favorable Safety Profile in Psoriasis
A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis.
https://t.co/84zS8VET6B https://t.co/aLvLmmTc93
Links:
Dr. John Cush RheumNow ( View Tweet)